| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 222 | 2023 | 2261 | 28.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 134 | 2023 | 1074 | 22.910 |
Why?
|
| Proto-Oncogene Proteins c-met | 77 | 2020 | 199 | 17.690 |
Why?
|
| Antineoplastic Agents | 69 | 2021 | 2357 | 7.600 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 34 | 2022 | 153 | 7.070 |
Why?
|
| Neoplasms | 50 | 2023 | 2897 | 6.230 |
Why?
|
| Carcinoma, Small Cell | 30 | 2014 | 134 | 6.230 |
Why?
|
| Protein Kinase Inhibitors | 42 | 2023 | 589 | 5.900 |
Why?
|
| Small Cell Lung Carcinoma | 20 | 2023 | 98 | 5.840 |
Why?
|
| Drug Resistance, Neoplasm | 37 | 2023 | 592 | 5.670 |
Why?
|
| Mesothelioma | 22 | 2020 | 311 | 5.380 |
Why?
|
| Hepatocyte Growth Factor | 25 | 2017 | 84 | 4.910 |
Why?
|
| Biomarkers, Tumor | 35 | 2021 | 1464 | 4.910 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 16 | 2023 | 154 | 4.710 |
Why?
|
| ErbB Receptors | 41 | 2023 | 485 | 4.540 |
Why?
|
| Mutation | 64 | 2023 | 3967 | 4.420 |
Why?
|
| Humans | 413 | 2023 | 86601 | 3.870 |
Why?
|
| Gene Expression Regulation, Neoplastic | 44 | 2023 | 1197 | 3.700 |
Why?
|
| Proto-Oncogene Proteins | 37 | 2023 | 645 | 3.560 |
Why?
|
| Signal Transduction | 84 | 2023 | 3241 | 3.510 |
Why?
|
| Protein-Tyrosine Kinases | 32 | 2019 | 302 | 3.300 |
Why?
|
| Carcinoma, Squamous Cell | 23 | 2021 | 1075 | 3.100 |
Why?
|
| Cell Line, Tumor | 75 | 2023 | 2426 | 3.090 |
Why?
|
| Molecular Targeted Therapy | 19 | 2021 | 266 | 3.000 |
Why?
|
| Pyrazoles | 18 | 2023 | 153 | 3.000 |
Why?
|
| GTPase-Activating Proteins | 12 | 2022 | 65 | 2.970 |
Why?
|
| Piperazines | 23 | 2021 | 272 | 2.930 |
Why?
|
| Paxillin | 22 | 2016 | 59 | 2.870 |
Why?
|
| Brain Neoplasms | 10 | 2020 | 763 | 2.860 |
Why?
|
| ATP-Binding Cassette Transporters | 10 | 2021 | 141 | 2.770 |
Why?
|
| Adenocarcinoma | 25 | 2020 | 1169 | 2.740 |
Why?
|
| Pyridines | 17 | 2018 | 309 | 2.730 |
Why?
|
| Precision Medicine | 11 | 2023 | 395 | 2.730 |
Why?
|
| Receptor, EphB4 | 6 | 2018 | 24 | 2.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2021 | 2436 | 2.650 |
Why?
|
| Antibodies, Monoclonal | 19 | 2022 | 1376 | 2.610 |
Why?
|
| Cell Movement | 42 | 2020 | 758 | 2.590 |
Why?
|
| Neoplasm Proteins | 16 | 2021 | 532 | 2.400 |
Why?
|
| Indoles | 18 | 2014 | 318 | 2.260 |
Why?
|
| Pyrimidines | 16 | 2020 | 370 | 2.250 |
Why?
|
| Pleural Neoplasms | 12 | 2019 | 188 | 2.230 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 1052 | 2.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2021 | 930 | 2.070 |
Why?
|
| Exons | 6 | 2020 | 450 | 2.050 |
Why?
|
| Animals | 130 | 2023 | 26581 | 1.990 |
Why?
|
| Neovascularization, Pathologic | 15 | 2021 | 353 | 1.970 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 14 | 2017 | 36 | 1.920 |
Why?
|
| Receptors, Growth Factor | 13 | 2011 | 52 | 1.920 |
Why?
|
| Cell Proliferation | 37 | 2023 | 1578 | 1.900 |
Why?
|
| Phosphorylation | 45 | 2020 | 1106 | 1.900 |
Why?
|
| Xenograft Model Antitumor Assays | 26 | 2021 | 458 | 1.790 |
Why?
|
| Aged | 99 | 2023 | 18402 | 1.750 |
Why?
|
| Prognosis | 39 | 2023 | 3674 | 1.690 |
Why?
|
| Sulfonamides | 17 | 2022 | 300 | 1.670 |
Why?
|
| Melanoma | 7 | 2021 | 454 | 1.600 |
Why?
|
| Female | 140 | 2023 | 44507 | 1.570 |
Why?
|
| Mitochondria | 5 | 2020 | 535 | 1.570 |
Why?
|
| Fusion Proteins, bcr-abl | 20 | 2004 | 107 | 1.560 |
Why?
|
| Carboplatin | 10 | 2018 | 286 | 1.540 |
Why?
|
| Focal Adhesion Kinase 1 | 11 | 2018 | 31 | 1.540 |
Why?
|
| Phosphoproteins | 22 | 2003 | 254 | 1.540 |
Why?
|
| Apoptosis | 27 | 2021 | 1683 | 1.510 |
Why?
|
| Enzyme Inhibitors | 12 | 2020 | 639 | 1.490 |
Why?
|
| Sulfones | 5 | 2018 | 43 | 1.450 |
Why?
|
| Etoposide | 7 | 2017 | 196 | 1.440 |
Why?
|
| Mice | 77 | 2023 | 11352 | 1.430 |
Why?
|
| Male | 117 | 2023 | 40956 | 1.410 |
Why?
|
| Cytoskeletal Proteins | 15 | 2003 | 223 | 1.400 |
Why?
|
| Cell Survival | 21 | 2021 | 969 | 1.380 |
Why?
|
| Oncogene Proteins, Fusion | 7 | 2022 | 128 | 1.360 |
Why?
|
| Receptors, CXCR4 | 5 | 2023 | 44 | 1.350 |
Why?
|
| Cell Transformation, Neoplastic | 21 | 2019 | 427 | 1.330 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 37 | 1.320 |
Why?
|
| Middle Aged | 92 | 2022 | 25017 | 1.310 |
Why?
|
| Carcinoma | 4 | 2023 | 436 | 1.310 |
Why?
|
| RNA, Small Interfering | 21 | 2017 | 547 | 1.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 19 | 2019 | 262 | 1.240 |
Why?
|
| Pancreatic Neoplasms | 6 | 2022 | 645 | 1.230 |
Why?
|
| Cytoskeleton | 7 | 2003 | 193 | 1.200 |
Why?
|
| Peptides, Cyclic | 2 | 2017 | 43 | 1.180 |
Why?
|
| Caenorhabditis elegans | 5 | 2016 | 223 | 1.180 |
Why?
|
| DNA Topoisomerases, Type I | 5 | 2020 | 23 | 1.160 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2023 | 426 | 1.140 |
Why?
|
| Cisplatin | 9 | 2023 | 612 | 1.140 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2022 | 381 | 1.110 |
Why?
|
| DNA Mutational Analysis | 8 | 2020 | 526 | 1.110 |
Why?
|
| DNA, Neoplasm | 5 | 2019 | 265 | 1.100 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2017 | 70 | 1.100 |
Why?
|
| Aged, 80 and over | 46 | 2022 | 6501 | 1.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2018 | 108 | 1.100 |
Why?
|
| Fractals | 2 | 2016 | 42 | 1.090 |
Why?
|
| Kidney Neoplasms | 5 | 2023 | 621 | 1.040 |
Why?
|
| Cell Adhesion | 16 | 2020 | 420 | 1.040 |
Why?
|
| Gene Rearrangement | 7 | 2016 | 170 | 1.030 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 250 | 1.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 16 | 2002 | 302 | 1.030 |
Why?
|
| Neoplasm Metastasis | 17 | 2020 | 1056 | 1.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 10 | 2008 | 79 | 1.010 |
Why?
|
| Acetylcysteine | 3 | 2022 | 69 | 1.000 |
Why?
|
| Clinical Trials as Topic | 13 | 2019 | 1169 | 1.000 |
Why?
|
| Gene Dosage | 9 | 2013 | 207 | 0.990 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 56 | 0.980 |
Why?
|
| Lung | 12 | 2023 | 1170 | 0.960 |
Why?
|
| Chylous Ascites | 1 | 2023 | 9 | 0.940 |
Why?
|
| STAT3 Transcription Factor | 4 | 2021 | 78 | 0.930 |
Why?
|
| Oncogenes | 10 | 2019 | 88 | 0.920 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 298 | 0.920 |
Why?
|
| Neoplasm Staging | 30 | 2023 | 1937 | 0.910 |
Why?
|
| Medical Oncology | 3 | 2022 | 359 | 0.910 |
Why?
|
| Mitochondrial Dynamics | 2 | 2014 | 53 | 0.910 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 137 | 0.900 |
Why?
|
| Esophageal Neoplasms | 7 | 2017 | 321 | 0.900 |
Why?
|
| Insulins | 1 | 2022 | 6 | 0.880 |
Why?
|
| Paired Box Transcription Factors | 5 | 2015 | 50 | 0.880 |
Why?
|
| Systems Biology | 1 | 2023 | 42 | 0.880 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2023 | 100 | 0.880 |
Why?
|
| Peptide Hormones | 1 | 2022 | 29 | 0.870 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2019 | 2600 | 0.870 |
Why?
|
| In Situ Hybridization, Fluorescence | 10 | 2016 | 348 | 0.860 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2022 | 185 | 0.860 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 325 | 0.850 |
Why?
|
| Adult | 63 | 2022 | 25640 | 0.850 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 329 | 0.850 |
Why?
|
| Cell Adhesion Molecules | 8 | 2000 | 163 | 0.840 |
Why?
|
| Genetic Testing | 2 | 2016 | 535 | 0.830 |
Why?
|
| Protein Kinase C-alpha | 3 | 2021 | 27 | 0.830 |
Why?
|
| Thymus Neoplasms | 3 | 2022 | 41 | 0.820 |
Why?
|
| Tumor Cells, Cultured | 27 | 2021 | 1041 | 0.820 |
Why?
|
| Intrinsically Disordered Proteins | 4 | 2022 | 8 | 0.820 |
Why?
|
| Gene Expression | 8 | 2020 | 1284 | 0.820 |
Why?
|
| Myositis | 1 | 2021 | 17 | 0.810 |
Why?
|
| Organophosphorus Compounds | 3 | 2018 | 55 | 0.800 |
Why?
|
| Genome, Human | 2 | 2017 | 756 | 0.800 |
Why?
|
| Platinum | 1 | 2021 | 63 | 0.800 |
Why?
|
| Maternal Inheritance | 1 | 2021 | 4 | 0.800 |
Why?
|
| Models, Biological | 9 | 2021 | 1749 | 0.790 |
Why?
|
| Gene Amplification | 9 | 2017 | 131 | 0.790 |
Why?
|
| Janus Kinase 2 | 2 | 2021 | 57 | 0.790 |
Why?
|
| Piperidines | 3 | 2020 | 181 | 0.790 |
Why?
|
| Focal Adhesions | 2 | 2013 | 69 | 0.790 |
Why?
|
| Treatment Outcome | 30 | 2023 | 7988 | 0.790 |
Why?
|
| Myocarditis | 1 | 2021 | 50 | 0.790 |
Why?
|
| Nuclear Proteins | 17 | 2022 | 696 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-akt | 13 | 2021 | 322 | 0.780 |
Why?
|
| Stomach Neoplasms | 5 | 2020 | 266 | 0.780 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 83 | 0.780 |
Why?
|
| Phthalazines | 1 | 2021 | 39 | 0.770 |
Why?
|
| Flavanones | 6 | 2021 | 35 | 0.760 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2020 | 1 | 0.750 |
Why?
|
| Retrospective Studies | 30 | 2023 | 8475 | 0.750 |
Why?
|
| Mice, Nude | 15 | 2020 | 790 | 0.750 |
Why?
|
| Cell Cycle | 12 | 2014 | 502 | 0.750 |
Why?
|
| Thoracic Neoplasms | 3 | 2019 | 64 | 0.740 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 158 | 0.720 |
Why?
|
| Reactive Oxygen Species | 11 | 2014 | 480 | 0.710 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2022 | 456 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 317 | 0.710 |
Why?
|
| Breast Neoplasms | 12 | 2021 | 2887 | 0.700 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 182 | 0.690 |
Why?
|
| Carbazoles | 2 | 2018 | 51 | 0.680 |
Why?
|
| Immunohistochemistry | 15 | 2017 | 1753 | 0.680 |
Why?
|
| Carcinoma, Large Cell | 6 | 2021 | 39 | 0.680 |
Why?
|
| Hematopoietic Stem Cells | 10 | 2000 | 292 | 0.660 |
Why?
|
| Thymoma | 2 | 2022 | 30 | 0.660 |
Why?
|
| Mutation, Missense | 4 | 2010 | 276 | 0.660 |
Why?
|
| Immunotherapy | 5 | 2023 | 629 | 0.660 |
Why?
|
| Ubiquitin-Protein Ligases | 10 | 2017 | 165 | 0.660 |
Why?
|
| Tyrosine | 17 | 2020 | 133 | 0.650 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2021 | 2270 | 0.630 |
Why?
|
| Quinazolines | 10 | 2012 | 220 | 0.610 |
Why?
|
| Energy Metabolism | 1 | 2019 | 271 | 0.610 |
Why?
|
| Cetuximab | 9 | 2022 | 113 | 0.600 |
Why?
|
| Topoisomerase I Inhibitors | 4 | 2017 | 33 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 81 | 0.600 |
Why?
|
| Indazoles | 3 | 2014 | 68 | 0.600 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 20 | 0.600 |
Why?
|
| Disease-Free Survival | 12 | 2018 | 1204 | 0.580 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 159 | 0.570 |
Why?
|
| eIF-2 Kinase | 1 | 2016 | 46 | 0.570 |
Why?
|
| Peritoneal Neoplasms | 3 | 2013 | 176 | 0.560 |
Why?
|
| Survival Rate | 18 | 2021 | 1860 | 0.560 |
Why?
|
| Immunoblotting | 8 | 2017 | 268 | 0.560 |
Why?
|
| Nicotine | 2 | 2016 | 194 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2021 | 1313 | 0.550 |
Why?
|
| Cell Cycle Proteins | 4 | 2022 | 388 | 0.550 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 418 | 0.550 |
Why?
|
| Survival Analysis | 10 | 2021 | 1538 | 0.540 |
Why?
|
| Drug Synergism | 7 | 2018 | 303 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 3 | 2011 | 24 | 0.530 |
Why?
|
| Amino Acid Sequence | 13 | 2016 | 2062 | 0.530 |
Why?
|
| Microscopy, Atomic Force | 1 | 2015 | 52 | 0.530 |
Why?
|
| Transfection | 17 | 2019 | 896 | 0.520 |
Why?
|
| Myeloid Cells | 2 | 2012 | 98 | 0.520 |
Why?
|
| Early Detection of Cancer | 4 | 2021 | 392 | 0.520 |
Why?
|
| Disease Progression | 18 | 2020 | 1531 | 0.520 |
Why?
|
| Neoplasm Invasiveness | 6 | 2010 | 552 | 0.510 |
Why?
|
| Education, Continuing | 1 | 2014 | 11 | 0.510 |
Why?
|
| Drug Delivery Systems | 3 | 2014 | 178 | 0.510 |
Why?
|
| Remote Consultation | 1 | 2014 | 16 | 0.510 |
Why?
|
| Disease Models, Animal | 12 | 2023 | 2232 | 0.510 |
Why?
|
| Bevacizumab | 8 | 2023 | 281 | 0.500 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2016 | 109 | 0.500 |
Why?
|
| Gene Knockdown Techniques | 7 | 2021 | 236 | 0.500 |
Why?
|
| Cell Division | 13 | 2007 | 696 | 0.500 |
Why?
|
| Tumor Burden | 7 | 2016 | 288 | 0.500 |
Why?
|
| Combined Modality Therapy | 11 | 2021 | 1685 | 0.490 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2014 | 19 | 0.490 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2014 | 16 | 0.490 |
Why?
|
| MicroRNAs | 5 | 2023 | 534 | 0.490 |
Why?
|
| Education, Distance | 1 | 2014 | 25 | 0.490 |
Why?
|
| Maximum Tolerated Dose | 8 | 2020 | 270 | 0.490 |
Why?
|
| Erlotinib Hydrochloride | 11 | 2016 | 90 | 0.490 |
Why?
|
| Epidermal Growth Factor | 5 | 2022 | 119 | 0.480 |
Why?
|
| Protein Binding | 18 | 2020 | 1456 | 0.480 |
Why?
|
| Pyrazines | 5 | 2021 | 92 | 0.480 |
Why?
|
| PAX5 Transcription Factor | 3 | 2018 | 32 | 0.480 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2013 | 379 | 0.480 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 579 | 0.480 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 50 | 0.480 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 1204 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 860 | 0.470 |
Why?
|
| Genomics | 6 | 2023 | 720 | 0.470 |
Why?
|
| Niacinamide | 1 | 2013 | 116 | 0.470 |
Why?
|
| Fibroblast Growth Factors | 1 | 2014 | 80 | 0.470 |
Why?
|
| Community Health Services | 1 | 2014 | 80 | 0.460 |
Why?
|
| RNA Interference | 8 | 2021 | 369 | 0.460 |
Why?
|
| Radiosurgery | 3 | 2023 | 272 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 864 | 0.460 |
Why?
|
| Myokymia | 1 | 2013 | 3 | 0.460 |
Why?
|
| Proteomics | 4 | 2020 | 212 | 0.450 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 23 | 0.450 |
Why?
|
| Ovarian Neoplasms | 6 | 2023 | 744 | 0.450 |
Why?
|
| Neuralgia | 1 | 2013 | 28 | 0.450 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 45 | 0.450 |
Why?
|
| Calgranulin B | 1 | 2012 | 16 | 0.440 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 48 | 0.440 |
Why?
|
| Telomere | 1 | 2013 | 108 | 0.440 |
Why?
|
| Genetic Heterogeneity | 3 | 2021 | 62 | 0.440 |
Why?
|
| Follow-Up Studies | 12 | 2023 | 3636 | 0.440 |
Why?
|
| Genes, abl | 5 | 2020 | 12 | 0.430 |
Why?
|
| Proteome | 2 | 2018 | 124 | 0.430 |
Why?
|
| Liver Neoplasms | 6 | 2023 | 735 | 0.430 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 9 | 2004 | 173 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2019 | 1961 | 0.430 |
Why?
|
| Biopsy | 7 | 2021 | 1161 | 0.430 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 107 | 0.420 |
Why?
|
| Molecular Typing | 1 | 2012 | 17 | 0.420 |
Why?
|
| Gene Expression Profiling | 6 | 2017 | 1384 | 0.420 |
Why?
|
| Hepatitis C | 1 | 2014 | 208 | 0.420 |
Why?
|
| Cell Line | 30 | 2018 | 2468 | 0.420 |
Why?
|
| Video Recording | 1 | 2013 | 190 | 0.420 |
Why?
|
| ras Proteins | 6 | 2016 | 128 | 0.410 |
Why?
|
| Phenotype | 7 | 2021 | 2377 | 0.410 |
Why?
|
| Anticarcinogenic Agents | 3 | 2021 | 70 | 0.410 |
Why?
|
| Tissue Array Analysis | 5 | 2017 | 124 | 0.410 |
Why?
|
| DNA Damage | 1 | 2013 | 366 | 0.410 |
Why?
|
| Clathrin | 2 | 2022 | 29 | 0.400 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.390 |
Why?
|
| Benzamides | 8 | 2018 | 229 | 0.390 |
Why?
|
| Angiogenic Proteins | 1 | 2011 | 17 | 0.390 |
Why?
|
| Endocytosis | 4 | 2021 | 177 | 0.390 |
Why?
|
| Primary Health Care | 1 | 2014 | 339 | 0.390 |
Why?
|
| Protein Kinase C | 3 | 2017 | 270 | 0.390 |
Why?
|
| Multimodal Imaging | 3 | 2019 | 110 | 0.390 |
Why?
|
| beta Catenin | 2 | 2023 | 251 | 0.380 |
Why?
|
| Sirolimus | 2 | 2018 | 169 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2012 | 261 | 0.380 |
Why?
|
| Neuroblastoma | 2 | 2012 | 374 | 0.380 |
Why?
|
| Receptor, EphA2 | 1 | 2010 | 6 | 0.380 |
Why?
|
| Camptothecin | 3 | 2017 | 189 | 0.370 |
Why?
|
| Immune Tolerance | 1 | 2012 | 337 | 0.370 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2008 | 78 | 0.360 |
Why?
|
| Genetic Therapy | 3 | 2021 | 342 | 0.360 |
Why?
|
| Topotecan | 2 | 2006 | 45 | 0.360 |
Why?
|
| Protein Structure, Tertiary | 5 | 2015 | 736 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2023 | 21 | 0.360 |
Why?
|
| Molecular Sequence Data | 13 | 2015 | 3030 | 0.350 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 63 | 0.350 |
Why?
|
| Base Sequence | 10 | 2013 | 2330 | 0.340 |
Why?
|
| Pneumonectomy | 5 | 2022 | 196 | 0.340 |
Why?
|
| Microscopy, Video | 5 | 2004 | 34 | 0.340 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2021 | 124 | 0.340 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2020 | 157 | 0.340 |
Why?
|
| Prostatic Neoplasms | 4 | 2011 | 1720 | 0.340 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 21 | 0.340 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 894 | 0.340 |
Why?
|
| Up-Regulation | 5 | 2021 | 712 | 0.340 |
Why?
|
| Glycolysis | 3 | 2019 | 129 | 0.340 |
Why?
|
| Cell Nucleus | 5 | 2017 | 579 | 0.330 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 857 | 0.330 |
Why?
|
| Vulva | 1 | 2008 | 23 | 0.320 |
Why?
|
| Dacarbazine | 2 | 2013 | 102 | 0.320 |
Why?
|
| Neoplastic Stem Cells | 3 | 2020 | 143 | 0.320 |
Why?
|
| Models, Molecular | 4 | 2020 | 1286 | 0.320 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2012 | 44 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3352 | 0.310 |
Why?
|
| Machine Learning | 4 | 2023 | 232 | 0.310 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 33 | 0.300 |
Why?
|
| Neuroendocrine Tumors | 2 | 2010 | 105 | 0.300 |
Why?
|
| Chemokines | 2 | 2022 | 73 | 0.300 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2006 | 2 | 0.300 |
Why?
|
| Quinolones | 2 | 2018 | 60 | 0.300 |
Why?
|
| Databases, Factual | 1 | 2011 | 812 | 0.300 |
Why?
|
| Quality of Life | 4 | 2023 | 1583 | 0.300 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2005 | 114 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2013 | 407 | 0.300 |
Why?
|
| Quality Improvement | 2 | 2021 | 428 | 0.300 |
Why?
|
| Positron-Emission Tomography | 5 | 2023 | 329 | 0.290 |
Why?
|
| Cancer Vaccines | 4 | 2021 | 156 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 6 | 2014 | 927 | 0.290 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 188 | 0.290 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 6 | 2012 | 80 | 0.280 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 71 | 0.280 |
Why?
|
| Triazoles | 4 | 2015 | 96 | 0.280 |
Why?
|
| Computational Biology | 3 | 2021 | 528 | 0.280 |
Why?
|
| Lymphatic Metastasis | 5 | 2014 | 481 | 0.280 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2003 | 112 | 0.270 |
Why?
|
| Drug Design | 2 | 2021 | 124 | 0.270 |
Why?
|
| Enzyme Activation | 7 | 2013 | 692 | 0.270 |
Why?
|
| Sarcoma, Ewing | 2 | 2022 | 42 | 0.270 |
Why?
|
| Area Under Curve | 4 | 2020 | 334 | 0.270 |
Why?
|
| Paclitaxel | 4 | 2018 | 460 | 0.270 |
Why?
|
| Metformin | 2 | 2018 | 128 | 0.270 |
Why?
|
| Chemoradiotherapy | 4 | 2022 | 301 | 0.260 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2016 | 76 | 0.260 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 916 | 0.260 |
Why?
|
| Receptors, Eph Family | 1 | 2004 | 2 | 0.260 |
Why?
|
| Ephrins | 1 | 2004 | 2 | 0.260 |
Why?
|
| Imatinib Mesylate | 7 | 2004 | 126 | 0.260 |
Why?
|
| Registries | 2 | 2020 | 702 | 0.260 |
Why?
|
| Carcinogenesis | 3 | 2022 | 195 | 0.260 |
Why?
|
| Peptides | 2 | 2022 | 639 | 0.260 |
Why?
|
| Radiation Tolerance | 3 | 2023 | 168 | 0.260 |
Why?
|
| Keratins | 3 | 2004 | 63 | 0.260 |
Why?
|
| Pulmonary Fibrosis | 1 | 2006 | 123 | 0.260 |
Why?
|
| Tissue Distribution | 4 | 2020 | 290 | 0.260 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 223 | 0.260 |
Why?
|
| Pemetrexed | 5 | 2018 | 76 | 0.250 |
Why?
|
| Neuregulin-1 | 2 | 2022 | 13 | 0.250 |
Why?
|
| Disease Management | 2 | 2018 | 327 | 0.250 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 150 | 0.250 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2018 | 276 | 0.250 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 44 | 0.250 |
Why?
|
| Chemokines, CXC | 3 | 2002 | 21 | 0.250 |
Why?
|
| Morpholines | 3 | 2016 | 65 | 0.250 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 103 | 0.250 |
Why?
|
| Blotting, Western | 7 | 2015 | 782 | 0.250 |
Why?
|
| Endothelial Cells | 3 | 2014 | 428 | 0.250 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 9 | 2015 | 28 | 0.250 |
Why?
|
| Glioma | 1 | 2006 | 285 | 0.250 |
Why?
|
| Haptoglobins | 1 | 2004 | 9 | 0.250 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2018 | 137 | 0.240 |
Why?
|
| Epithelial Cells | 4 | 2013 | 669 | 0.240 |
Why?
|
| Protein Phosphatase 2 | 2 | 2021 | 15 | 0.240 |
Why?
|
| Lipopolysaccharides | 3 | 2015 | 286 | 0.240 |
Why?
|
| Aniline Compounds | 3 | 2021 | 55 | 0.240 |
Why?
|
| Fibronectins | 3 | 2003 | 93 | 0.240 |
Why?
|
| Loss of Heterozygosity | 2 | 2017 | 85 | 0.240 |
Why?
|
| Algorithms | 5 | 2022 | 1830 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 189 | 0.240 |
Why?
|
| Carrier Proteins | 3 | 2022 | 673 | 0.240 |
Why?
|
| Forkhead Box Protein M1 | 3 | 2023 | 13 | 0.240 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2020 | 371 | 0.240 |
Why?
|
| Sarcoma, Small Cell | 1 | 2003 | 1 | 0.240 |
Why?
|
| Ligands | 4 | 2020 | 433 | 0.240 |
Why?
|
| Eye Proteins | 2 | 2009 | 128 | 0.240 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 383 | 0.230 |
Why?
|
| Urogenital Neoplasms | 1 | 2023 | 23 | 0.230 |
Why?
|
| Drugs, Investigational | 1 | 2004 | 37 | 0.230 |
Why?
|
| Pubic Bone | 1 | 2003 | 9 | 0.230 |
Why?
|
| Chemotaxis | 2 | 2003 | 72 | 0.230 |
Why?
|
| Anilides | 2 | 2015 | 47 | 0.230 |
Why?
|
| Young Adult | 7 | 2022 | 5974 | 0.230 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 1999 | 11 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2010 | 65 | 0.230 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 24 | 0.230 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2023 | 36 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 21 | 0.220 |
Why?
|
| Histones | 2 | 2017 | 311 | 0.220 |
Why?
|
| Cytokines | 3 | 2022 | 776 | 0.220 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2010 | 176 | 0.220 |
Why?
|
| Adipokines | 1 | 2022 | 19 | 0.220 |
Why?
|
| Mice, Inbred NOD | 6 | 2019 | 187 | 0.220 |
Why?
|
| Cross Reactions | 1 | 2022 | 106 | 0.220 |
Why?
|
| Immune System Diseases | 1 | 2023 | 26 | 0.220 |
Why?
|
| Tobacco Use Cessation | 1 | 2022 | 7 | 0.220 |
Why?
|
| Receptors, Notch | 2 | 2019 | 120 | 0.220 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 280 | 0.220 |
Why?
|
| DNA Primers | 4 | 2013 | 543 | 0.220 |
Why?
|
| Origin of Life | 1 | 2022 | 4 | 0.220 |
Why?
|
| Celecoxib | 2 | 2019 | 31 | 0.220 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2022 | 19 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 70 | 0.220 |
Why?
|
| Cell Growth Processes | 5 | 2014 | 83 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2003 | 136 | 0.210 |
Why?
|
| Carcinogens | 1 | 2022 | 108 | 0.210 |
Why?
|
| Volvox | 1 | 2022 | 1 | 0.210 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 541 | 0.210 |
Why?
|
| Capecitabine | 2 | 2019 | 96 | 0.210 |
Why?
|
| Estradiol | 1 | 2003 | 252 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 138 | 0.210 |
Why?
|
| Oxidative Stress | 2 | 2022 | 447 | 0.210 |
Why?
|
| Finches | 1 | 2022 | 55 | 0.210 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1540 | 0.210 |
Why?
|
| Chemokine CXCL12 | 4 | 2010 | 37 | 0.210 |
Why?
|
| Fatal Outcome | 3 | 2013 | 293 | 0.200 |
Why?
|
| Point Mutation | 2 | 2013 | 246 | 0.200 |
Why?
|
| Transducin | 1 | 2021 | 1 | 0.200 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 108 | 0.200 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 938 | 0.200 |
Why?
|
| Drug Utilization | 1 | 2022 | 65 | 0.200 |
Why?
|
| Receptor, ErbB-3 | 3 | 2017 | 18 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 176 | 0.200 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 188 | 0.200 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 13 | 0.200 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2021 | 44 | 0.200 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2018 | 11 | 0.200 |
Why?
|
| CA-125 Antigen | 1 | 2001 | 22 | 0.200 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2001 | 15 | 0.200 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2001 | 41 | 0.200 |
Why?
|
| Virus Diseases | 1 | 2021 | 97 | 0.200 |
Why?
|
| Acrylamides | 2 | 2018 | 30 | 0.200 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 45 | 0.200 |
Why?
|
| Intermediate Filament Proteins | 1 | 2001 | 35 | 0.200 |
Why?
|
| Wound Healing | 2 | 2014 | 344 | 0.200 |
Why?
|
| Proteins | 6 | 1997 | 777 | 0.200 |
Why?
|
| Pyridazines | 1 | 2020 | 22 | 0.200 |
Why?
|
| Emigration and Immigration | 1 | 2021 | 48 | 0.200 |
Why?
|
| Drug Tolerance | 1 | 2021 | 63 | 0.200 |
Why?
|
| Retreatment | 2 | 2018 | 107 | 0.190 |
Why?
|
| Administration, Oral | 5 | 2014 | 684 | 0.190 |
Why?
|
| Integrin beta1 | 4 | 2004 | 33 | 0.190 |
Why?
|
| src Homology Domains | 7 | 2000 | 44 | 0.190 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2020 | 4 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 279 | 0.190 |
Why?
|
| Biological Products | 1 | 2023 | 143 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 238 | 0.190 |
Why?
|
| B-Lymphocytes | 7 | 2018 | 724 | 0.190 |
Why?
|
| Zebrafish | 1 | 2023 | 309 | 0.190 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 41 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 199 | 0.190 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 18 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 301 | 0.190 |
Why?
|
| RNA | 3 | 2021 | 560 | 0.190 |
Why?
|
| Drug Therapy | 1 | 2020 | 70 | 0.190 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 70 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 479 | 0.190 |
Why?
|
| Flow Cytometry | 4 | 2010 | 679 | 0.190 |
Why?
|
| Proteolysis | 2 | 2017 | 100 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2020 | 33 | 0.180 |
Why?
|
| Cell Size | 4 | 2004 | 65 | 0.180 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2020 | 41 | 0.180 |
Why?
|
| Jejunal Neoplasms | 1 | 2000 | 9 | 0.180 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 23 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 214 | 0.180 |
Why?
|
| Risk Factors | 9 | 2021 | 5416 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 78 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2021 | 182 | 0.180 |
Why?
|
| Sequence Analysis, Protein | 1 | 2020 | 28 | 0.180 |
Why?
|
| Smoking Cessation | 1 | 2022 | 230 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 13 | 0.180 |
Why?
|
| Mucins | 1 | 2020 | 39 | 0.180 |
Why?
|
| Alternative Splicing | 3 | 2015 | 201 | 0.180 |
Why?
|
| Mice, SCID | 5 | 2019 | 252 | 0.180 |
Why?
|
| Smoking | 4 | 2013 | 609 | 0.180 |
Why?
|
| Aminopyridines | 2 | 2017 | 38 | 0.180 |
Why?
|
| Genes, erbB-1 | 2 | 2010 | 16 | 0.180 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2019 | 21 | 0.180 |
Why?
|
| Antiviral Agents | 1 | 2023 | 510 | 0.180 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 9 | 0.180 |
Why?
|
| Boronic Acids | 2 | 2011 | 55 | 0.180 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2016 | 63 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2013 | 273 | 0.180 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 49 | 0.180 |
Why?
|
| Talin | 2 | 1996 | 2 | 0.180 |
Why?
|
| United States | 9 | 2019 | 6665 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 134 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2019 | 51 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 97 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 64 | 0.170 |
Why?
|
| Cell Count | 3 | 2017 | 195 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2022 | 530 | 0.170 |
Why?
|
| Cell Line, Transformed | 7 | 2003 | 154 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1034 | 0.170 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1998 | 16 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 879 | 0.170 |
Why?
|
| Drug Interactions | 2 | 2019 | 248 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2015 | 30 | 0.170 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 339 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 5 | 2009 | 74 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2021 | 280 | 0.160 |
Why?
|
| Cytogenetics | 1 | 1998 | 27 | 0.160 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2018 | 44 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 853 | 0.160 |
Why?
|
| Lipoproteins | 1 | 1998 | 135 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2021 | 482 | 0.160 |
Why?
|
| Chromosome Aberrations | 4 | 2012 | 387 | 0.160 |
Why?
|
| Antigens, CD | 5 | 2015 | 458 | 0.160 |
Why?
|
| Mortality | 1 | 2019 | 149 | 0.160 |
Why?
|
| Reference Values | 2 | 2015 | 674 | 0.160 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 488 | 0.160 |
Why?
|
| Recurrence | 2 | 2018 | 1139 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2020 | 391 | 0.160 |
Why?
|
| Interleukin-3 | 6 | 1999 | 36 | 0.160 |
Why?
|
| Carbon | 1 | 2018 | 80 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 394 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 291 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 1998 | 90 | 0.150 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1196 | 0.150 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 128 | 0.150 |
Why?
|
| Survivorship | 1 | 2017 | 18 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 149 | 0.150 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 269 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2002 | 416 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2017 | 53 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2014 | 155 | 0.150 |
Why?
|
| Binding Sites | 8 | 2015 | 1098 | 0.150 |
Why?
|
| HEK293 Cells | 3 | 2015 | 615 | 0.150 |
Why?
|
| Antibodies | 3 | 2018 | 350 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2011 | 311 | 0.150 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 100 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 689 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2023 | 138 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2023 | 4210 | 0.150 |
Why?
|
| Glucose | 2 | 2018 | 638 | 0.150 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 1208 | 0.150 |
Why?
|
| Thiophenes | 1 | 2017 | 48 | 0.150 |
Why?
|
| 3T3 Cells | 4 | 2015 | 94 | 0.150 |
Why?
|
| Lactams, Macrocyclic | 3 | 2017 | 14 | 0.150 |
Why?
|
| Glutamates | 4 | 2014 | 89 | 0.150 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2019 | 245 | 0.150 |
Why?
|
| Anthracyclines | 2 | 2022 | 37 | 0.150 |
Why?
|
| Ubiquitin | 1 | 2017 | 93 | 0.150 |
Why?
|
| Translocation, Genetic | 3 | 2012 | 265 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 101 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2016 | 38 | 0.140 |
Why?
|
| Infant | 2 | 2022 | 3045 | 0.140 |
Why?
|
| Integrin beta4 | 2 | 2012 | 2 | 0.140 |
Why?
|
| Receptors, Chemokine | 2 | 2010 | 31 | 0.140 |
Why?
|
| Microtubules | 1 | 2016 | 119 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 3 | 2012 | 303 | 0.140 |
Why?
|
| Time Factors | 9 | 2019 | 5209 | 0.140 |
Why?
|
| Guanine | 4 | 2014 | 208 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2017 | 85 | 0.140 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 20 | 0.140 |
Why?
|
| Sequence Alignment | 2 | 2015 | 351 | 0.140 |
Why?
|
| Obesity | 1 | 2022 | 963 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2020 | 1351 | 0.130 |
Why?
|
| Pseudopodia | 2 | 2014 | 35 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2018 | 839 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 503 | 0.130 |
Why?
|
| Luteinizing Hormone | 1 | 2015 | 167 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 261 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2015 | 83 | 0.130 |
Why?
|
| Hypogonadism | 1 | 2015 | 37 | 0.130 |
Why?
|
| Endocrine Disruptors | 1 | 2015 | 27 | 0.130 |
Why?
|
| Fertility | 1 | 2016 | 115 | 0.130 |
Why?
|
| Skin | 3 | 2008 | 554 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 469 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 93 | 0.130 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 67 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 123 | 0.130 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 296 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 86 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 114 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2015 | 41 | 0.130 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 16 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 5 | 0.130 |
Why?
|
| Fibroblasts | 3 | 2014 | 729 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2000 | 557 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2501 | 0.130 |
Why?
|
| Michigan | 1 | 2014 | 52 | 0.130 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 26 | 0.130 |
Why?
|
| Ephrin-A2 | 1 | 2014 | 3 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 316 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 375 | 0.130 |
Why?
|
| Locomotion | 1 | 2016 | 131 | 0.130 |
Why?
|
| Bronchi | 2 | 2013 | 229 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 56 | 0.130 |
Why?
|
| Alleles | 1 | 2018 | 1127 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2009 | 68 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 1135 | 0.120 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 60 | 0.120 |
Why?
|
| Goats | 1 | 2014 | 18 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 166 | 0.120 |
Why?
|
| PAX8 Transcription Factor | 1 | 2014 | 23 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2014 | 49 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 57 | 0.120 |
Why?
|
| NADPH Oxidases | 2 | 2014 | 81 | 0.120 |
Why?
|
| Protein Engineering | 1 | 2015 | 140 | 0.120 |
Why?
|
| Genotype | 4 | 2014 | 1850 | 0.120 |
Why?
|
| Protein Transport | 5 | 2020 | 411 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1994 | 165 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.120 |
Why?
|
| Testosterone | 1 | 2015 | 271 | 0.120 |
Why?
|
| Inhibitor of Growth Protein 1 | 1 | 2013 | 1 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 123 | 0.120 |
Why?
|
| Quinolines | 1 | 2014 | 95 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 81 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 6 | 2018 | 3092 | 0.120 |
Why?
|
| Mutant Proteins | 1 | 2014 | 94 | 0.120 |
Why?
|
| Carcinoid Tumor | 2 | 2004 | 42 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 36 | 0.120 |
Why?
|
| Integrins | 3 | 2000 | 76 | 0.120 |
Why?
|
| Hematopoiesis | 1 | 1994 | 163 | 0.120 |
Why?
|
| Exanthema | 1 | 2014 | 36 | 0.120 |
Why?
|
| Imidazoles | 1 | 2014 | 162 | 0.120 |
Why?
|
| Breath Tests | 1 | 2013 | 55 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 1294 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 54 | 0.120 |
Why?
|
| Membrane Fluidity | 1 | 1993 | 8 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 74 | 0.120 |
Why?
|
| Megakaryocytes | 4 | 2000 | 36 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2014 | 144 | 0.120 |
Why?
|
| Gene Silencing | 3 | 2014 | 172 | 0.120 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 9 | 0.110 |
Why?
|
| Deoxycytidine | 4 | 2015 | 237 | 0.110 |
Why?
|
| Autopsy | 1 | 2013 | 116 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2011 | 233 | 0.110 |
Why?
|
| Bone and Bones | 1 | 1994 | 265 | 0.110 |
Why?
|
| Oligonucleotides | 1 | 2013 | 92 | 0.110 |
Why?
|
| Cellular Senescence | 1 | 2013 | 94 | 0.110 |
Why?
|
| Protein Isoforms | 3 | 2019 | 270 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1994 | 156 | 0.110 |
Why?
|
| Chromones | 2 | 2002 | 28 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 184 | 0.110 |
Why?
|
| Cells, Cultured | 8 | 2015 | 2818 | 0.110 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2012 | 36 | 0.110 |
Why?
|
| Fetus | 1 | 2014 | 226 | 0.110 |
Why?
|
| Hospice Care | 1 | 2013 | 39 | 0.110 |
Why?
|
| Growth Substances | 2 | 2003 | 80 | 0.110 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2010 | 23 | 0.110 |
Why?
|
| Adolescent | 4 | 2022 | 8979 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 435 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2011 | 28 | 0.110 |
Why?
|
| Telomerase | 2 | 2003 | 55 | 0.110 |
Why?
|
| Quinones | 2 | 2002 | 9 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2020 | 628 | 0.110 |
Why?
|
| Electromyography | 1 | 2013 | 183 | 0.110 |
Why?
|
| Azabicyclo Compounds | 1 | 2012 | 3 | 0.110 |
Why?
|
| Benzoquinones | 2 | 2002 | 27 | 0.110 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 39 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 937 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2022 | 1565 | 0.110 |
Why?
|
| Pleura | 1 | 2012 | 30 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 172 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases | 4 | 2000 | 46 | 0.110 |
Why?
|
| Animals, Genetically Modified | 2 | 2014 | 181 | 0.110 |
Why?
|
| Shock, Septic | 1 | 1993 | 102 | 0.110 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2012 | 48 | 0.110 |
Why?
|
| Hydrogen Peroxide | 4 | 2007 | 158 | 0.110 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2013 | 122 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 93 | 0.100 |
Why?
|
| Radiology | 1 | 2014 | 194 | 0.100 |
Why?
|
| Precancerous Conditions | 2 | 2010 | 196 | 0.100 |
Why?
|
| Heterografts | 2 | 2023 | 98 | 0.100 |
Why?
|
| Capillary Permeability | 2 | 2015 | 130 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2011 | 25 | 0.100 |
Why?
|
| Calcium | 2 | 2015 | 1156 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 327 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 287 | 0.100 |
Why?
|
| Cadherins | 2 | 2015 | 151 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 4 | 2011 | 425 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 54 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 125 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2008 | 64 | 0.100 |
Why?
|
| Tropism | 1 | 2011 | 4 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 192 | 0.100 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2011 | 9 | 0.100 |
Why?
|
| Lysophospholipids | 2 | 2011 | 63 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 171 | 0.100 |
Why?
|
| src-Family Kinases | 4 | 2017 | 74 | 0.100 |
Why?
|
| Microvessels | 1 | 2011 | 70 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1804 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 113 | 0.100 |
Why?
|
| Cell Death | 1 | 2012 | 256 | 0.100 |
Why?
|
| CD2 Antigens | 2 | 2002 | 22 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 70 | 0.100 |
Why?
|
| Genes, ras | 1 | 2011 | 96 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2012 | 260 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2011 | 256 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 194 | 0.100 |
Why?
|
| Palliative Care | 1 | 2013 | 257 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2006 | 322 | 0.100 |
Why?
|
| Cell Shape | 1 | 2011 | 51 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 268 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 184 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2019 | 2767 | 0.100 |
Why?
|
| Protein Conformation | 3 | 2022 | 881 | 0.090 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2010 | 30 | 0.090 |
Why?
|
| Glycosylation | 2 | 2021 | 129 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2022 | 197 | 0.090 |
Why?
|
| SOXE Transcription Factors | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2019 | 1924 | 0.090 |
Why?
|
| Mass Screening | 3 | 2012 | 617 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 179 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 78 | 0.090 |
Why?
|
| Antibody Formation | 2 | 2008 | 171 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.090 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.090 |
Why?
|
| Mammary Glands, Animal | 2 | 2021 | 78 | 0.090 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2009 | 38 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 449 | 0.090 |
Why?
|
| Protein Domains | 2 | 2020 | 128 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2011 | 329 | 0.090 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2019 | 12 | 0.090 |
Why?
|
| Breast | 2 | 2023 | 286 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 413 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 279 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2012 | 394 | 0.090 |
Why?
|
| Thiocarbamates | 2 | 2007 | 6 | 0.090 |
Why?
|
| Molecular Biology | 2 | 2016 | 89 | 0.090 |
Why?
|
| Recombinant Proteins | 7 | 2002 | 1014 | 0.090 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2008 | 9 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2009 | 45 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 66 | 0.090 |
Why?
|
| Phosphotyrosine | 5 | 2007 | 32 | 0.090 |
Why?
|
| Gene Editing | 2 | 2021 | 42 | 0.090 |
Why?
|
| Cloning, Molecular | 5 | 2012 | 646 | 0.090 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2000 | 51 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2019 | 70 | 0.090 |
Why?
|
| Phorbol Esters | 1 | 2008 | 22 | 0.080 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 16 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 79 | 0.080 |
Why?
|
| Thrombopoietin | 3 | 1999 | 12 | 0.080 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 38 | 0.080 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 106 | 0.080 |
Why?
|
| DNA Repair | 2 | 2021 | 356 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2008 | 35 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2008 | 56 | 0.080 |
Why?
|
| Liver | 1 | 1993 | 1229 | 0.080 |
Why?
|
| Dynamin II | 1 | 2007 | 15 | 0.080 |
Why?
|
| Amino Acid Motifs | 2 | 2015 | 116 | 0.080 |
Why?
|
| Cortactin | 1 | 2007 | 11 | 0.080 |
Why?
|
| Protein Kinase C-delta | 1 | 2007 | 26 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2007 | 36 | 0.080 |
Why?
|
| Antioxidants | 2 | 2007 | 223 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 307 | 0.080 |
Why?
|
| Autoantigens | 1 | 2008 | 127 | 0.080 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 135 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2007 | 21 | 0.080 |
Why?
|
| Muridae | 1 | 2007 | 8 | 0.080 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.080 |
Why?
|
| Consensus | 2 | 2019 | 335 | 0.080 |
Why?
|
| Calcinosis | 1 | 2008 | 224 | 0.080 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 51 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 73 | 0.080 |
Why?
|
| Vinculin | 2 | 1997 | 9 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2020 | 2261 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2012 | 926 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 129 | 0.070 |
Why?
|
| California | 2 | 2021 | 138 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2008 | 160 | 0.070 |
Why?
|
| GTP-Binding Proteins | 3 | 2010 | 146 | 0.070 |
Why?
|
| Proline | 1 | 2007 | 57 | 0.070 |
Why?
|
| Physicians | 1 | 2014 | 673 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 297 | 0.070 |
Why?
|
| Cytoplasm | 3 | 2002 | 281 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 1997 | 113 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 314 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2021 | 1981 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1458 | 0.070 |
Why?
|
| Social Class | 1 | 2007 | 127 | 0.070 |
Why?
|
| Genes, src | 2 | 1997 | 6 | 0.070 |
Why?
|
| Stem Cells | 1 | 2008 | 351 | 0.070 |
Why?
|
| Rats | 4 | 2003 | 3990 | 0.070 |
Why?
|
| Microfilament Proteins | 2 | 1999 | 208 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2009 | 403 | 0.070 |
Why?
|
| Dyspnea | 1 | 2006 | 73 | 0.070 |
Why?
|
| Multigene Family | 1 | 2006 | 202 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 304 | 0.070 |
Why?
|
| Ribs | 1 | 2006 | 45 | 0.070 |
Why?
|
| Cell Membrane | 3 | 2020 | 666 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 1996 | 256 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2021 | 104 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2006 | 61 | 0.070 |
Why?
|
| Patient Selection | 3 | 2019 | 685 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 536 | 0.070 |
Why?
|
| Bone Marrow | 3 | 1997 | 435 | 0.070 |
Why?
|
| Transcriptome | 2 | 2021 | 580 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1673 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2705 | 0.060 |
Why?
|
| Epithelium | 1 | 2005 | 319 | 0.060 |
Why?
|
| Collagen Type IV | 1 | 2004 | 24 | 0.060 |
Why?
|
| Biomarkers | 3 | 2014 | 1718 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2006 | 255 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 332 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2015 | 46 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 763 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 74 | 0.060 |
Why?
|
| Phytochemicals | 1 | 2023 | 5 | 0.060 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2023 | 1 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2004 | 209 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 1195 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2017 | 361 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2003 | 40 | 0.060 |
Why?
|
| Pupa | 1 | 2023 | 14 | 0.060 |
Why?
|
| PAX3 Transcription Factor | 2 | 2015 | 11 | 0.060 |
Why?
|
| Kinetics | 5 | 1999 | 1513 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 103 | 0.060 |
Why?
|
| Threonine | 2 | 2013 | 33 | 0.060 |
Why?
|
| Stem Cell Factor | 3 | 1999 | 19 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2004 | 106 | 0.060 |
Why?
|
| Body Fluids | 1 | 2003 | 36 | 0.060 |
Why?
|
| Tubulin | 1 | 2003 | 58 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 104 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2003 | 47 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 376 | 0.060 |
Why?
|
| Superoxides | 1 | 2003 | 73 | 0.060 |
Why?
|
| Papillomaviridae | 2 | 2014 | 153 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 50 | 0.060 |
Why?
|
| Reference Standards | 1 | 2023 | 159 | 0.060 |
Why?
|
| Injections | 1 | 2003 | 109 | 0.060 |
Why?
|
| Beak | 1 | 2022 | 9 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 25 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 13 | 0.050 |
Why?
|
| China | 1 | 2003 | 228 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 136 | 0.050 |
Why?
|
| Immunologic Surveillance | 1 | 2002 | 14 | 0.050 |
Why?
|
| Microscopy | 1 | 2003 | 87 | 0.050 |
Why?
|
| Endothelins | 1 | 2022 | 35 | 0.050 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 19 | 0.050 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2002 | 9 | 0.050 |
Why?
|
| Incidence | 1 | 2007 | 1576 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2023 | 315 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 99 | 0.050 |
Why?
|
| Fluorescein | 1 | 2002 | 16 | 0.050 |
Why?
|
| Drug Eruptions | 1 | 2002 | 35 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 86 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2002 | 44 | 0.050 |
Why?
|
| Ethanolamines | 1 | 2002 | 32 | 0.050 |
Why?
|
| Advisory Committees | 2 | 2012 | 90 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 55 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2002 | 94 | 0.050 |
Why?
|
| Protein Interaction Maps | 1 | 2022 | 48 | 0.050 |
Why?
|
| Lymphokines | 1 | 2001 | 76 | 0.050 |
Why?
|
| Canada | 2 | 2012 | 204 | 0.050 |
Why?
|
| Taxoids | 2 | 2015 | 129 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 179 | 0.050 |
Why?
|
| Inflammation | 2 | 2023 | 920 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2022 | 126 | 0.050 |
Why?
|
| Organelles | 1 | 2022 | 52 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 203 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 254 | 0.050 |
Why?
|
| Sialyltransferases | 1 | 2021 | 1 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 103 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2002 | 728 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mucin 5AC | 1 | 2021 | 8 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 286 | 0.050 |
Why?
|
| Antagomirs | 1 | 2021 | 3 | 0.050 |
Why?
|
| Clinical Studies as Topic | 1 | 2021 | 4 | 0.050 |
Why?
|
| Leukemia, Myeloid | 2 | 2010 | 249 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2012 | 227 | 0.050 |
Why?
|
| RNA, Antisense | 1 | 2021 | 15 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 49 | 0.050 |
Why?
|
| Keratin-20 | 1 | 2001 | 6 | 0.050 |
Why?
|
| Keratin-7 | 1 | 2001 | 10 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 36 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 37 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 38 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2002 | 155 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2012 | 219 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2001 | 271 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 352 | 0.050 |
Why?
|
| Cardiolipins | 1 | 2020 | 17 | 0.050 |
Why?
|
| A549 Cells | 1 | 2020 | 39 | 0.050 |
Why?
|
| Anthracenes | 1 | 2020 | 16 | 0.050 |
Why?
|
| U937 Cells | 1 | 2020 | 32 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 79 | 0.050 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2000 | 38 | 0.050 |
Why?
|
| Age of Onset | 1 | 2021 | 310 | 0.050 |
Why?
|
| Crk-Associated Substrate Protein | 2 | 1997 | 2 | 0.050 |
Why?
|
| Cell Communication | 1 | 2021 | 194 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 678 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p130 | 2 | 1997 | 7 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 68 | 0.050 |
Why?
|
| Receptors, Interleukin | 1 | 2000 | 35 | 0.050 |
Why?
|
| Cytochalasin D | 2 | 1999 | 14 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2000 | 86 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2019 | 27 | 0.050 |
Why?
|
| Genes | 1 | 2000 | 305 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2002 | 460 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1047 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 34 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2003 | 471 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 217 | 0.040 |
Why?
|
| Blood Cells | 2 | 1996 | 33 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 287 | 0.040 |
Why?
|
| Mice, Inbred SENCAR | 1 | 2019 | 4 | 0.040 |
Why?
|
| Bortezomib | 2 | 2011 | 76 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2013 | 285 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 45 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 151 | 0.040 |
Why?
|
| Hippocalcin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Recoverin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 222 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 408 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 65 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2020 | 105 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 102 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 567 | 0.040 |
Why?
|
| Comorbidity | 2 | 2012 | 943 | 0.040 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 84 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2000 | 246 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2018 | 18 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 11 | 0.040 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1997 | 1 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 1998 | 115 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 25 | 0.040 |
Why?
|
| Remission Induction | 2 | 2011 | 722 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Leukemia | 1 | 2020 | 320 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1997 | 34 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 428 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2001 | 307 | 0.040 |
Why?
|
| Ku Autoantigen | 1 | 2017 | 12 | 0.040 |
Why?
|
| Age Factors | 2 | 2012 | 1849 | 0.040 |
Why?
|
| Erythropoietin | 1 | 1997 | 91 | 0.040 |
Why?
|
| Lactams | 1 | 2017 | 10 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2017 | 16 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 196 | 0.040 |
Why?
|
| Self-Management | 1 | 2017 | 29 | 0.040 |
Why?
|
| Actins | 2 | 1997 | 451 | 0.040 |
Why?
|
| Vanadates | 3 | 2004 | 29 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2017 | 67 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 31 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 1997 | 158 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2017 | 75 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2016 | 3 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 95 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1997 | 233 | 0.040 |
Why?
|
| Hemorrhage | 2 | 1989 | 268 | 0.040 |
Why?
|
| Phylogeny | 1 | 2002 | 1137 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1996 | 66 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 2216 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2016 | 10 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 268 | 0.030 |
Why?
|
| Tensins | 1 | 1995 | 1 | 0.030 |
Why?
|
| Self Care | 1 | 2017 | 164 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 396 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 200 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 1997 | 232 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1996 | 177 | 0.030 |
Why?
|
| Milk Proteins | 1 | 1995 | 24 | 0.030 |
Why?
|
| Blastomycosis | 1 | 1995 | 6 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 26 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 363 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 65 | 0.030 |
Why?
|
| Cell Surface Display Techniques | 1 | 2015 | 16 | 0.030 |
Why?
|
| Benzocycloheptenes | 1 | 2015 | 2 | 0.030 |
Why?
|
| Tyrphostins | 1 | 2015 | 7 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 68 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 99 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 1995 | 21 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 129 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 113 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 157 | 0.030 |
Why?
|
| Abscess | 1 | 1995 | 91 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 2 | 2010 | 42 | 0.030 |
Why?
|
| Technetium | 1 | 1994 | 28 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1565 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 212 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2016 | 140 | 0.030 |
Why?
|
| Biological Evolution | 1 | 2022 | 918 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 101 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 220 | 0.030 |
Why?
|
| Rabbits | 1 | 1995 | 636 | 0.030 |
Why?
|
| Introns | 1 | 2015 | 289 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 63 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1995 | 105 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 332 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 393 | 0.030 |
Why?
|
| Thymidine Kinase | 1 | 2014 | 30 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 220 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 75 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
| Integrases | 1 | 2014 | 59 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 112 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1994 | 49 | 0.030 |
Why?
|
| Methotrexate | 1 | 1994 | 249 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 299 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 485 | 0.030 |
Why?
|
| Anesthetics | 1 | 2014 | 48 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1994 | 295 | 0.030 |
Why?
|
| Precipitin Tests | 3 | 2001 | 108 | 0.030 |
Why?
|
| Pneumonia | 1 | 1995 | 179 | 0.030 |
Why?
|
| Diltiazem | 1 | 1993 | 17 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 1993 | 9 | 0.030 |
Why?
|
| Workload | 1 | 2014 | 128 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 266 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 121 | 0.030 |
Why?
|
| Rats, Inbred Strains | 1 | 1993 | 312 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 357 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 305 | 0.030 |
Why?
|
| Methionine | 1 | 2013 | 66 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 119 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2013 | 104 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 378 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 130 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1994 | 556 | 0.030 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 54 | 0.030 |
Why?
|
| Chromatin | 1 | 2015 | 380 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 2356 | 0.030 |
Why?
|
| Microcirculation | 1 | 2012 | 106 | 0.030 |
Why?
|
| Acetylation | 1 | 2012 | 121 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1993 | 253 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 114 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 439 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 133 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 1990 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 365 | 0.030 |
Why?
|
| Sulfites | 1 | 2012 | 26 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 167 | 0.030 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2011 | 14 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2011 | 24 | 0.030 |
Why?
|
| Electrophysiology | 1 | 2012 | 401 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 1074 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 439 | 0.030 |
Why?
|
| International Agencies | 1 | 2011 | 34 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 239 | 0.030 |
Why?
|
| Australia | 1 | 2011 | 99 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 18 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 134 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2011 | 121 | 0.030 |
Why?
|
| Metalloporphyrins | 1 | 2011 | 26 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 244 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 23 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 159 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 20 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
| NADP | 1 | 2010 | 45 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 396 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1185 | 0.020 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2009 | 12 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 145 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 421 | 0.020 |
Why?
|
| Aminocaproates | 1 | 1989 | 4 | 0.020 |
Why?
|
| PAX6 Transcription Factor | 1 | 2009 | 10 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2000 | 2 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2010 | 127 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2009 | 70 | 0.020 |
Why?
|
| Bilirubin | 1 | 2009 | 125 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 567 | 0.020 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 2 | 2000 | 4 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 677 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 912 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 108 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 44 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 268 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.020 |
Why?
|
| COS Cells | 1 | 2008 | 166 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 63 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2008 | 94 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1989 | 183 | 0.020 |
Why?
|
| Hemostasis | 1 | 1987 | 21 | 0.020 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2007 | 8 | 0.020 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2007 | 25 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2007 | 15 | 0.020 |
Why?
|
| Genes, Intracisternal A-Particle | 1 | 2007 | 3 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 307 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 596 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2007 | 20 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3611 | 0.020 |
Why?
|
| Acetophenones | 1 | 2007 | 27 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 20 | 0.020 |
Why?
|
| Software | 1 | 2012 | 654 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 31 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 152 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 364 | 0.020 |
Why?
|
| Integrin alpha5beta1 | 1 | 2007 | 13 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1989 | 241 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 207 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2007 | 112 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-crk | 2 | 1997 | 9 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 408 | 0.020 |
Why?
|
| Furans | 1 | 1986 | 16 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 695 | 0.020 |
Why?
|
| Monensin | 1 | 1986 | 16 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 751 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1986 | 40 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 911 | 0.020 |
Why?
|
| Cricetinae | 2 | 2002 | 560 | 0.020 |
Why?
|
| Homeostasis | 1 | 2007 | 409 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2007 | 328 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 999 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 159 | 0.020 |
Why?
|
| Phloretin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Caspases | 1 | 2005 | 155 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2004 | 37 | 0.020 |
Why?
|
| K562 Cells | 1 | 2004 | 43 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 20 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2004 | 77 | 0.020 |
Why?
|
| Genistein | 1 | 2004 | 16 | 0.020 |
Why?
|
| Thrombosis | 1 | 1987 | 296 | 0.020 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 73 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2007 | 243 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 330 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 199 | 0.020 |
Why?
|
| Macrophages | 1 | 1987 | 554 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 509 | 0.010 |
Why?
|
| Child | 1 | 2014 | 6926 | 0.010 |
Why?
|
| Integrin alpha4 | 1 | 2002 | 11 | 0.010 |
Why?
|
| Oncogene Protein v-cbl | 1 | 2002 | 1 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2002 | 10 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2002 | 10 | 0.010 |
Why?
|
| Vitamin E Deficiency | 1 | 2002 | 3 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2002 | 83 | 0.010 |
Why?
|
| Benzene Derivatives | 1 | 2002 | 7 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 56 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 187 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 93 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 156 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 59 | 0.010 |
Why?
|
| Exocytosis | 1 | 2001 | 108 | 0.010 |
Why?
|
| Vinblastine | 1 | 2001 | 108 | 0.010 |
Why?
|
| Kidney | 1 | 1987 | 1241 | 0.010 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2000 | 2 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 46 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2002 | 255 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 91 | 0.010 |
Why?
|
| Rotenone | 1 | 2000 | 17 | 0.010 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2000 | 4 | 0.010 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2000 | 5 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 504 | 0.010 |
Why?
|
| Nocodazole | 1 | 1999 | 18 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 1141 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 111 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2000 | 229 | 0.010 |
Why?
|
| Mercaptoethanol | 1 | 1999 | 8 | 0.010 |
Why?
|
| Genes, fos | 1 | 1999 | 24 | 0.010 |
Why?
|
| CD58 Antigens | 1 | 1998 | 5 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1998 | 14 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 68 | 0.010 |
Why?
|
| Risk | 1 | 2000 | 674 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 347 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 104 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 1999 | 58 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 123 | 0.010 |
Why?
|
| Cell Polarity | 1 | 1998 | 115 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1997 | 9 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1997 | 13 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1998 | 195 | 0.010 |
Why?
|
| Leukocytes | 1 | 1998 | 202 | 0.010 |
Why?
|
| Spleen | 1 | 1998 | 430 | 0.010 |
Why?
|
| Son of Sevenless Proteins | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 376 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 1997 | 30 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1997 | 129 | 0.010 |
Why?
|
| Contrast Media | 1 | 2002 | 1077 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2000 | 434 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1996 | 54 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 86 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1995 | 4 | 0.010 |
Why?
|
| TYK2 Kinase | 1 | 1995 | 7 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 1995 | 15 | 0.010 |
Why?
|
| Receptors, Cytokine | 1 | 1995 | 28 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1995 | 52 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 126 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1994 | 47 | 0.010 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1994 | 5 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1994 | 6 | 0.010 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1994 | 9 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1996 | 464 | 0.010 |
Why?
|
| Trans-Activators | 1 | 1995 | 429 | 0.010 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1989 | 6 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1989 | 14 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1989 | 60 | 0.010 |
Why?
|
| Fibrinopeptide A | 1 | 1987 | 3 | 0.010 |
Why?
|
| Protein C | 1 | 1987 | 5 | 0.010 |
Why?
|
| Antithrombin III | 1 | 1987 | 9 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1987 | 20 | 0.000 |
Why?
|
| Pregnancy | 1 | 1995 | 2893 | 0.000 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1987 | 39 | 0.000 |
Why?
|
| Catalase | 1 | 1987 | 48 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1987 | 45 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1987 | 72 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1986 | 32 | 0.000 |
Why?
|
| Acetates | 1 | 1986 | 66 | 0.000 |
Why?
|
| Lipoproteins, LDL | 1 | 1986 | 83 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1986 | 90 | 0.000 |
Why?
|
| Phospholipids | 1 | 1986 | 111 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1986 | 130 | 0.000 |
Why?
|
| Cholesterol | 1 | 1986 | 356 | 0.000 |
Why?
|